{"ok":true,"trend":{"id":470576,"platform":"news","region":"global","key":"engineering better agonistic antibodies for cancer immunotherapy","title":"Engineering Better Agonistic Antibodies for Cancer Immunotherapy","url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQa2tzNlhWVHNBQUljdWljMHpnSnFlX0EycXlmN09VZ3lqZWRCRlRndkNMaEhkY3VaeFVXM2p1eHpidHR2VVRZQ1RRLW9lZkJoQWVQS3dPZ19keHQyMlF3aDVQSVhETmM3VTRhcDNIendKcU9yOC1QWWRWZ296MVF4Q2NsN3h3TFRPVzJDUnlkQm5NTTd2cjMxVGx6VnB2cS1DX3FjNTcwck1tN1ZQSE1obWRwUThmTDV6cFE?oc=5","first_seen":"2026-09-30T10:07:51.801612Z","last_seen":"2026-09-30T10:07:51.801612Z","last_rank":29,"peak_rank":29,"last_volume":null,"peak_volume":null,"seen_count":1,"score":0.7184375,"category_hint":"technology","section":"technology","category":"technology","summary":"New coverage from Technology Networks examines efforts to design improved agonistic antibodies, drugs that activate immune-cell receptors to help the body attack tumours. The piece outlines how engineering strategies aim to enhance their potency and safety for cancer immunotherapy, a fast-growing field where several agonistic antibody candidates have struggled to show clinical benefit so far.","why":"Ongoing interest in improving cancer immunotherapy as researchers seek safer, more effective ways to activate anti-tumour immune responses.","tone":"neutral","entities":["Technology Networks","agonistic antibodies","cancer immunotherapy"],"summarized_at":"2026-09-30T10:10:36.009687Z","meta":{"via":"scan","lang":"en","term":"technology","source":"Technology Networks","published":"Wed, 30 Sep 2026 09:10:59 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Engineering Better Agonistic Antibodies for Cancer Immunotherapy","section_name":"Technology","category_name":"Technology","timeline":[{"captured_at":"2026-09-30T10:07:51.801612Z","rank":29,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQa2tzNlhWVHNBQUljdWljMHpnSnFlX0EycXlmN09VZ3lqZWRCRlRndkNMaEhkY3VaeFVXM2p1eHpidHR2VVRZQ1RRLW9lZkJoQWVQS3dPZ19keHQyMlF3aDVQSVhETmM3VTRhcDNIendKcU9yOC1QWWRWZ296MVF4Q2NsN3h3TFRPVzJDUnlkQm5NTTd2cjMxVGx6VnB2cS1DX3FjNTcwck1tN1ZQSE1obWRwUThmTDV6cFE?oc=5","author":"Technology Networks","title":"Engineering Better Agonistic Antibodies for Cancer Immunotherapy","snippet":null,"posted_at":"2026-09-30T09:10:59Z","likes":null}],"elsewhere":[],"window":"7d"}}